RVP — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-15

• We have been manufacturing and marketing our products since 1997. Syringes comprised 80.8% of our sales in the first quarter of 2026. EasyPoint® products accounted for 13.8% and other products, including our IV safety catheter and blood collection products, were 5.4% of our sales in the first quarte…

• We expect international sales of VanishPoint syringes and EasyPoint needles to increase in the second half of 2026 following the recent certification under the European Union Medical Device Regulation 2017/745 which is required for the sale of medical devices within the European Union.

• On September 13, 2024, the Office of the U.S. Trade Representative (“USTR”) revealed final adjustments to increase tariffs on certain goods imported from China under Section 301 (“Section 301”) of the Trade Act of 1974 (“Trade Act”). Among those products included were syringes and needles, at a rate…

• 2026, a 10% ad valorem duty went into effect under Section 122 of the Trade Act. This duty is in addition to the above-mentioned Section 301 tariffs.

• As of May 1, 2026, the prevailing tariff rate on most syringe and needle products imported from China was 110%. Other products we import from China, which do not fall under the category of needles and syringes, are subject to a 10% tariff rate. As foreign trade policy continues to evolve, including …

Text removed vs the prior filing · source: 10-Q · 2025-11-14

• We have been manufacturing and marketing our products since 1997. Syringes comprised 65.0% of our sales in the first nine months of 2025. EasyPoint® products accounted for 31.3% and other products, including our IV safety catheter and blood collection products, were 3.7% of our sales in the first ni…

• On September 13, 2024, the Office of the U.S. Trade Representative (“USTR”) revealed final adjustments to increase tariffs on certain goods imported from China under Section 301 of the Trade Act of 1974. Among those products included were syringes and needles, at a rate of 100%. During 2025, the on-…

• While we have manufacturing capabilities to manufacture most of the products we currently sell domestically, some of our products are sourced exclusively from China. 61.7% and 90% of the products we obtained in the first nine months of 2025 and 2024, respectively, were purchased from our manufacture…

• We have recently adapted some equipment to increase our domestic manufacturing capabilities. The adaptations to existing equipment will allow us to produce 0.5 mL syringes domestically. Once operational, we will no longer rely on imports for these products. We currently anticipate that commercial qu…

• As detailed in Note 4 to the financial statements, we held $30.5 million in debt and equity securities as of September 30, 2025, which represented 20.8% of our total assets.

Text added vs the prior filing · source: 10-Q · 2026-05-15

• Since material weaknesses were reported as of December 31, 2025, we have improved our monthly close process and account reconciliations to prevent and/or detect misstatements in a timely manner. Management intends to continue to engage in strengthening review procedures, increasing the level of prec…

Text removed vs the prior filing · source: 10-Q · 2025-11-14

• There have been no changes during the third quarter of 2025 or subsequent to September 30, 2025, in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.